PSC PARTNERS SEEKING A CURE FINANCIAL STATEMENTS DECEMBER 31, 2017

CONTENTS

Independent Auditor's Report	2-3
Statements of Financial Position	4
Statements of Activities	5
Statements of Functional expenses	6
Statements of Cash Flows	7
Notes to Financial Statements	8-12



<u>Independent Auditor's Report</u>

Board of Directors PSC Partners Seeking A Cure Englewood, Colorado

I have audited the accompanying financial statements of PSC Partners Seeking A Cure (a Colorado not-for-profit organization) as of December 31, 2017, which comprise the statement of financial position as of December 31, 2017, and the related statements of activities, functional expenses and cash flows for the year then ended and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

My responsibility is to express an opinion on these financial statements based on my audit. I conducted my audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that I plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, I express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my audit opinion.

Opinion

In my opinion, the financial statements referred to above present fairly, in all material respects, the financial position of PSC Partners Seeking A Cure as of December 31, 2017, and the changes in its net assets and cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

Prior Period Financial Statements

The financial statements of PSC Partners Seeking A Cure as of December 31, 2016, were audited by another accounting firm whose report dated March 17, 2017, expressed an unmodified opinion on those statements.

fati a Associates, esc

September 5, 2018 Denver, Colorado

PSC PARTNERS SEEKING A CURE STATEMENTS OF FINANCIAL POSITION

December 31,	2017	2016
Assets Cash Investments Accounts receivable Prepaid expenses Equipment, net of accumulated depreciation Deposits	\$ 35,479 1,645,289 27,897 14,124 5,533 2,114	\$ 68,553 1,684,193 30,044 3,837 9,818 2,114
Total Assets	<u>\$ 1,730,436</u>	\$ 1,798,559
<u>Liabilities and Net Assets</u> Accounts payable and accrued liabilities	\$ 5,311	\$ 5,053
Net assets Unrestricted Temporarily restricted Total net assets	1,338,497 386,628 1,725,125	1,519,821 273,685 1,793,506
Total Liabilities and Net Assets	\$ 1,730,436	\$ 1,798,559

$\frac{\text{PSC PARTNERS SEEKING A CURE}}{\text{STATEMENTS OF ACTIVITIES}}$

	Unrestricted	Temporarily Restricted	Total
For the Year Ended December 31, 2017: Support, revenue and other gains Contributions Conference income Investment income Net assets released from restrictions Total support, revenue and other gains	\$ 342,434 0 49,502 288,339 680,275	\$ 166,520 234,762 0 (288,339) 112,943	\$ 508,954 234,762 49,502 0 793,218
Expenses Program General and administrative Fundraising Total expenses	691,658 80,608 89,333 861,599		691,658 80,608 89,333 861,599
Changes in net assets	(181,324)	112,943	(68,381)
Net assets, beginning of year	1,519,821	273,685	1,793,506
Net assets, end of year	<u>\$ 1,338,497</u>	<u>\$ 386,628</u>	<u>\$ 1,725,125</u>
For the Year Ended December 31, 2016: Support, revenue and other gains Contributions Conference income Investment income Net assets released from restrictions Total support, revenue and other gains	\$ 503,498 0 19,227 218,423 741,148	\$ 95,581 218,585 0 (218,423) 95,743	\$ 599,079 218,585 19,227 0 836,891
Expenses Program General and administrative Fundraising Total expenses	476,321 123,417 85,761 685,499		476,321 123,417 85,761 685,499
Changes in net assets	55,649	95,743	151,392
Net assets, beginning of year	1,464,172	177,942	1,642,114
Net assets, end of year	<u>\$ 1,519,821</u>	<u>\$ 273,685</u>	<u>\$ 1,793,506</u>

PSC PARTNERS SEEKING A CURE STATEMENTS OF FUNCTIONAL EXPENSES

	Program	General and Administrative	<u>Fundraising</u>	Totals
For the Year Ended December	31, 2017			
Salaries and wages	\$ 127,536	\$ 36,647	\$ 51,307	\$ 215,490
Employee benefits	7,486	2,151	3,012	12,649
Payroll taxes	<u>9,648</u>	2,773	3,882	16,303
Total compensation	144,670	41,571	58,201	244,442
Conference & meetings Professional fees Postage Insurance Grants to others Office expense Technology Marketing Occupancy Patient registry Depreciation Total expenses For the Year Ended December	120,168	10,682	2,670	133,520
	315	18,243	75	18,633
	616	47	284	947
	412	1,156	83	1,651
	333,000	0	0	333,000
	7,157	3,904	1,951	13,012
	8,508	2,320	4,641	15,469
	30,204	0	19,616	49,820
	25,193	1,355	542	27,090
	17,559	987	1,184	19,730
	3,856	343	86	4,285
	\$ 691,658	\$ 80,608	\$ 89,333	\$ 861,599
Salaries and wages Employee benefits Payroll taxes Total compensation	\$ 54,754	\$ 48,522	\$ 34,426	\$ 137,702
	4,730	3,527	2,752	11,009
	4,031	3,527	2,519	10,077
	63,515	55,576	39,697	158,788
Professional fees Postage Insurance Grants to others Office expense Conference & meetings Technology Marketing Rent Patient registry Depreciation Total expenses	5,424 222 352 282,960 6,115 71,534 8,685 4,142 15,273 15,516 2,583 \$ 476,321	10,848 240 1,233 0 5,336 33,016 6,204 1,625 4,364 2,715 2,260 \$ 123,417	1,808 461 176 0 3,837 5,503 9,925 19,394 2,182 1,164 1,614 \$ 85,761	$18,080$ 923 $1,761$ $282,960$ $15,288$ $110,053$ $24,814$ $25,161$ $21,819$ $19,395$ $\underline{6,457}$ $\$$ $685,499$

PSC PARTNERS SEEKING A CURE STATEMENTS OF CASH FLOWS

For the Years ended December 31,		2017		2016
Cash flows from operating activities				
Cash received from donors	\$	484,380	\$	544,363
Cash paid to vendors and suppliers		(867,343)		(680,582)
Other income received		234,762		218,585
Interest and dividends received		13,484		10,700
Net cash provided by (used in) operating activities	_	(134,717)		93,066
Cash flows from investing activities				
Purchase of fixed assets		0		(3,284)
Purchase of investments		(253,357)		(195,612)
Proceeds from sale of investments		355,000		75,000
Net cash provided by (used in) investing activities		101,643		(123,896)
Net decrease in cash and cash equivalents		(33,074)		(30,830)
Cash and cash equivalents at beginning of year	-	68,553		99,383
Cash and cash equivalents at end of year	\$	35,479	\$	68,553
Reconciliation of changes in net assets to net cash provided by (us	sed i	n) operating	activ	rities:
Changes in net assets	\$	(68,381)	\$	151,392
Reconciling adjustments		4.205		C 157
Depreciation		4,285		6,457
Gain on investments		(36,018)		(8,527)
Donated stock Change in apparating assets and lightilities.		(26,721)		(24,672)
Change in operating assets and liabilities: Accounts receivable		2 147		(20.044)
		2,147		(30,044)
Prepaid expenses		(10,287)		(959) (581)
Accrued liabilities and accounts payable	_	258		(581)
Net cash provided by (used in) operating activities	\$	(134,717)	\$	93,066

NOTE 1 - <u>DESCRIPTION OF ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</u>

PSC Partners Seeking A Cure (PSCP) is a Colorado non-profit organization. The mission of the PSC Partners Seeking A Cure is to provide education and support to PSC patients, families and caregivers and to raise funds to research causes, treatments and potential cures for primary sclerosing cholangitis.

PSCP, primary sclerosing cholangitis, is an immune-mediated disease that causes the bile ducts inside and outside the liver to become scarred, narrowed and eventually blocked. As more and more ducts are blocked, bile becomes trapped and damages the liver. The damage, if left unchecked, causes liver cell death, which leads to cirrhosis and may eventually require a liver transplant. At present, the only definitive treatment for primary sclerosing cholangitis is a liver transplantation. PSCP is working to find better treatments and a cure.

The Scientific/Medical Advisory Committee of PSCP annually evaluates research proposals and selects grants to promote PSC research. The PSC Partners Seeking a Cure Literature Site is a website providing information on PSCP and is updated weekly to provide PSC patients, caregivers, physicians, and researchers access to information concerning PSC and allied diseases. The website includes advice and personal stories from its members, in order to offer everyday living suggestions to PSCers in addition to updates on treatments and medical research. Starting in 2005 PSCP has held annual conferences for PSC patients and caregivers at medical centers throughout the country. These conferences allow the opportunity to learn about the most recent advances in PSC treatments and research, while also allowing PSCers to share their experiences, advice, and concerns with other PSCers. In addition, PSCP publishes a free online newsletter with updates about the latest treatments, research results, and coping suggestions. PSCP also holds local forums for PSC patients and caregivers.

Basis of Presentation

The financial statements are presented on the basis of unrestricted, temporarily restricted, and permanently restricted net assets.

Cash and Cash Equivalents

PSCP considers all highly liquid debt instruments with original maturities of three months or less to be cash equivalents.

Concentration of Credit Risk

PSCP has determined that current operational cash needs will occasionally result in cash and money market account balances in excess of insured limits.

Income Taxes

No provision for income taxes has been made in the accompanying financial statements because PSCP has qualified as exempt from income tax under Section 501 (c)(3) of the Internal Revenue Code (Code) and comparable state law, and contributions to it are tax deductible within the limitations prescribed by the Code. PSCP did not have any material unrelated business income tax liability or significant uncertain tax positions for the years ended December 31, 2017 or 2016. PSCP's tax filings are subject to audit by various taxing authorities. PSCP's ending open audit periods are December 31, 2014 through 2017.

NOTE 1 - DESCRIPTION OF ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

Revenue Recognition

PSCP reports gifts of cash and other assets as restricted support if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the statement of activities as net assets released from restrictions.

Donor restricted contributions whose restrictions are met in the same reporting periods are reported as unrestricted support in the statement of activities.

Contributions of services shall be recognized if the services received create or enhance nonfinancial assets or require specialized skills, are provided by individuals possessing those skills, and would typically need to be purchased if not provided by donation.

Advertising Costs

Advertising and promotion costs are expensed as incurred.

Reclassifications

Certain accounts in the prior year financial statements have been reclassified for comparative purposes to conform with the presentation in the current year financial statements.

Equipment and Depreciation

PSCP capitalizes all expenditures more than \$1,000 for property and equipment at cost. Contributed property and equipment is recorded at fair value at the date of donation. Depreciation is provided over the estimated useful lives of the respective assets on a straight-line basis. Routine repairs and maintenance are expensed as incurred.

Allocation of expenses

The costs of providing the various programs and supporting activities of PSCP have been summarized on a functional basis in the Statement of Activities. Accordingly, certain costs have been allocated among the programs and supporting activities benefited.

Subsequent Events

PSCP's financial statements were available to be issued on September 5, 2018, and this is the date through which subsequent events were evaluated. PSCP did not identify any subsequent events requiring disclosure.

NOTE 2 - **INVESTMENTS**

Investments held as of December 31 are as follows:

	2017	2016
Cash and cash equivalents Fixed income Mutual Funds-Bonds Mutual Funds-Equities	\$ 1,180,467 121,731 244,340 98,751	\$ 1,282,109 78,742 244,467 78,875
	<u>\$ 1,645,289</u>	<u>\$ 1,684,193</u>
Composition of investment return: Interest and dividends Realized and unrealized gain	\$ 13,484 36,018	\$ 10,700 8,527
	<u>\$ 49,502</u>	<u>\$ 19,227</u>

The fair value measurement accounting literature provides the framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). All of PSCP's investments are valued using Level 1, which are described as inputs to the valuation methodology which are unadjusted quoted prices for identical assets or liabilities in active markets that PSCP has the ability to access.

NOTE 3 - EQUIPMENT AND DEPRECIATION

	 2017	 2016
Computers and equipment Furniture and fixtures	\$ 18,186 2,489 20,675	\$ 18,186 2,489 20,675
Less accumulated depreciation	 (15,142)	 (10,857)
Net fixed assets	\$ 5,533	\$ 9,818

NOTE 4 - TEMPORARILY RESTRICTED NET ASSETS

Net assets were released from donor restrictions by incurring expenses satisfying the restricted purposes as follows:

	 2017	 2016
Information technology Patient registry Research Conference	\$ 15,469 400 141,120 131,350	\$ 26,048 12,308 70,581 109,486
	\$ 288,339	\$ 218,423

NOTE 4 - TEMPORARILY RESTRICTED NET ASSETS (CONTINUED)

Temporarily restricted net assets are available for the following purposes:

	 2017	 2016
Information technology Conference	\$ 104,803 281,825	\$ 95,272 178,413
	\$ 386,628	\$ 273,685

NOTE 5 - CONCENTRATIONS

Eleven percent of 2017 revenue and sixteen percent of 2016 revenue was received from the top two donors. PSCP monitors its cash flow so that it does not rely on large donations to perform its exempt purpose.

NOTE 6 - COMMITMENTS

PSCP has entered certain contracts for future conference venues. These contracts contain provisions for damages upon cancellation of the events. Management is confident the conferences will take place as planned and PSCP will not be in a position to pay cancellation penalties.

NOTE 7 - ENDOWMENTS

PSCP does not currently possess any true endowments, or permanently restricted gift instruments. PSCP has several temporarily restricted net asset balances related to its three pillar programs; research, awareness, and education. As required by generally accepted accounting principles, net assets associated with endowment funds, including temporarily restricted net asset balances, are classified and reported based on the existence or absence of donor imposed restrictions. Changes in temporarily restricted net assets for the years ended December 31, 2017 and 2016 are reflected in the statements of activities.

NOTE 8 - OPERATING LEASE COMMITMENTS

PSCP is leasing office space under a five-year noncancelable lease expiring March 2020. Total lease expense for 2017 and 2016 was \$27,090 and \$21,819 respectively.

The following is a schedule of minimum future rental payments required under the above operating lease for the years ending December 31:

2018	\$ 26,533
2019	27,201
2020	6.842

NOTE 9 - RETIREMENT PLAN

PSCP maintains a defined contribution pension plan (the Plan) as defined under Section 401(k) of the U.S. Internal Revenue Code covering substantially all employees. The Plan offers employees who are 21 years of age and have completed 3 months of service, the opportunity to voluntarily contribute to the Plan. As of December 31, 2017, PSCP did not make match voluntary contributions to the Plan.

NOTE 10 - AFFILIATE ORGANIZATION

PSCP entered in to an Affiliate Agreement in 2016 with Partners Seeking A Cure Canada, an organization registered as a Canadian not-for-profit corporation. The affiliate was formed to enable Canadian donors to receive tax credits for their donations to support the research of PSC. According to the restrictions of the affiliate's charity registration under Canadian charity law, PSC Partners Seeking A Cure Canada can only use donations to cover operating costs and to support research institutions which are included in a pre-approved list issued by the Canadian government. Research grants will be chosen per the same Scientific/Medical Advisory Committee procedures used by PSC Partners (USA).